Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
AstraZeneca
Modality
monoclonal_antibody
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
44Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02658214CT.gov Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors | — | Completed | — | — | — |
NCT02571725CT.gov PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Peritoneal Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Durvalumab (this asset) | AstraZeneca | P1/2 | CCC · 53 |
| Carboplatin | Eli Lilly and Company | P3 | BBB |
| Adriamycin | Eli Lilly and Company | P3 | BBB |
| (R)-(1-(4-Fluorophenyl)-6-((1-Methyl-1H-Pyrazol-4-Yl)Sulfonyl)-1,4,5,6,7,8-Hexahydro-4Ah-Pyrazolo(3,4-G)Isoquinolin-4A-Yl)(4-(Trifluoromethyl)Pyridin-2-Yl)Methanone | Corcept Therapeutics | P3 | BB |
| Patupilone | Novartis Pharmaceuticals | P3 | BB |
| Nogitecan | Eli Lilly and Company | P3 | BB |
| Fluorouracilum | AstraZeneca | P2 | BB |
| Olaparib | Merck Sharp & Dohme LLC | P3 | B |
| Oxaliplatin | Sun Yat-sen University | P2/3 | B |
+36 more in the Peritoneal Neoplasm cohort
Other indications for Durvalumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ovarian Carcinoma | — | P2 | BB · 70 |
| Primary Peritoneal Carcinoma | — | P2 | BB · 70 |
| Urothelial Carcinoma | — | P3 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- CarboplatinEli Lilly and CompanyBBB
- AdriamycinEli Lilly and CompanyBBB
- (R)-(1-(4-Fluorophenyl)-6-((1-Methyl-1H-Pyrazol-4-Yl)Sulfonyl)-1,4,5,6,7,8-Hexahydro-4Ah-Pyrazolo(3,4-G)Isoquinolin-4A-Yl)(4-(Trifluoromethyl)Pyridin-2-Yl)MethanoneCorcept TherapeuticsBB
- PatupiloneNovartis PharmaceuticalsBB
- NogitecanEli Lilly and CompanyBB
Citation
Floatz Terminal. Durvalumab in Peritoneal Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/durvalumab-peritoneal-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →